The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...

The report provides extensive insights into over 180 companies and 200 drugs in the PD-1 and PD-L1 inhibitors market. This comprehensive resource focuses on treatment assessments by product type, ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ... clinical results filed in support of the PD-1 inhibitor do not meet the criteria for foreign ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda ... form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb. The FDA approval is based on ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic ...